Insider Selling: Alphatec (NASDAQ:ATEC) Director Sells $3,864,000.00 in Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) Director Jeffrey Rydin sold 200,000 shares of the business’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $19.32, for a total transaction of $3,864,000.00. Following the completion of the sale, the director directly owned 385,441 shares of the company’s stock, valued at approximately $7,446,720.12. The trade was a 34.16% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Alphatec Stock Up 1.5%

Shares of NASDAQ ATEC opened at $19.80 on Friday. The firm has a market cap of $2.94 billion, a price-to-earnings ratio of -17.52 and a beta of 1.17. The company’s 50-day simple moving average is $15.63 and its 200-day simple moving average is $13.56. The company has a quick ratio of 1.77, a current ratio of 2.88 and a debt-to-equity ratio of 23.22. Alphatec Holdings, Inc. has a 52-week low of $8.18 and a 52-week high of $20.17.

Alphatec (NASDAQ:ATEC) last released its quarterly earnings results on Thursday, October 30th. The medical technology company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.09. The company had revenue of $196.50 million for the quarter, compared to analyst estimates of $182.78 million. During the same quarter last year, the company earned ($0.28) EPS. The firm’s revenue for the quarter was up 30.4% on a year-over-year basis. Alphatec has set its FY 2025 guidance at EPS. Equities analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Institutional Trading of Alphatec

A number of hedge funds and other institutional investors have recently modified their holdings of ATEC. Valeo Financial Advisors LLC boosted its position in shares of Alphatec by 2.1% during the 3rd quarter. Valeo Financial Advisors LLC now owns 41,296 shares of the medical technology company’s stock valued at $600,000 after acquiring an additional 846 shares during the last quarter. Norden Group LLC increased its position in Alphatec by 2.6% during the third quarter. Norden Group LLC now owns 36,676 shares of the medical technology company’s stock worth $533,000 after purchasing an additional 939 shares during the last quarter. Arizona State Retirement System raised its stake in Alphatec by 2.8% during the third quarter. Arizona State Retirement System now owns 34,603 shares of the medical technology company’s stock worth $503,000 after purchasing an additional 949 shares during the period. Ameritas Investment Partners Inc. boosted its holdings in Alphatec by 8.8% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 11,845 shares of the medical technology company’s stock valued at $131,000 after purchasing an additional 955 shares during the last quarter. Finally, Nisa Investment Advisors LLC boosted its holdings in Alphatec by 22.4% in the 2nd quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company’s stock valued at $63,000 after purchasing an additional 1,045 shares during the last quarter. 66.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on ATEC shares. Needham & Company LLC lifted their price target on Alphatec from $16.00 to $22.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Weiss Ratings restated a “sell (d-)” rating on shares of Alphatec in a report on Tuesday, October 14th. Piper Sandler reaffirmed an “overweight” rating and set a $25.00 target price (up previously from $20.00) on shares of Alphatec in a report on Friday, October 31st. Canaccord Genuity Group increased their target price on shares of Alphatec from $20.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Finally, Wall Street Zen upgraded shares of Alphatec from a “hold” rating to a “buy” rating in a research report on Saturday, October 18th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Alphatec currently has an average rating of “Moderate Buy” and an average price target of $22.11.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.